High acceptability of a contraceptive vaginal ring among women in Kigali, Rwanda

Evelyne Kestelyn1,2*, Jennifer Ilo Van Nuil1,2, Marie Michelle Umulisa1, Grace Umutoni1, Alice Uwingabire1, Lambert Mwambarangwe1, Mireille Uwineza1, Stephen Agaba1, Tania Crucitti3, Janneke van de Wijger2, Thérèse Delvaux3, for the Ring Plus Study Group

1 Rinda Ubuzima, Kigali, Rwanda, 2 University of Liverpool, Institute of Infection and Global Health, Liverpool, United Kingdom, 3 Institute of Tropical Medicine, Antwerp, Belgium

*Membership of the Ring Plus Study Group is provided in the Acknowledgments.

* ekestelyn@oucru.org

Abstract

Background
Introduction of contraceptive vaginal rings (CVRs) could expand the contraceptive method mix reducing the unmet need for family planning in Rwanda, but data on acceptability of CVRs from low and middle-income countries are lacking.

Methods
This study explores acceptability of contraceptive vaginal ring (NuvaRing) use in Kigali, Rwanda using a mixed methods approach. We collected quantitative and qualitative data before, during and after conducting a clinical trial, using Case Report Forms, Interviewer Administered Questionnaires, In Depth Interviews and Focus Group Discussions. We analyzed the data using an existing theoretical framework including product attributes, relationship attributes and sexual encounter attributes as well as the contextual environment.

Results
Our data showed that initial worries reduced over time with actual ring use and ring insertions and removals were described as easy. Most women did not feel the ring during daily activities, appreciated the lack of perceived negative side effects and the increased lubrication. Relationship attributes and sexual encounter attributes such as sexual comfort played a significant role in ring acceptability of the participants and their partners. The contextual environment including Rwandan cultural norms around sexuality positively influenced the acceptance of the NuvaRing. Overall satisfaction was high.

Conclusions
Acceptability of the Nuvaring was high among study participants and represents a promising option that could contribute to lowering the unmet need for family planning in Rwanda.
Introduction

Provision of family planning services remains inadequate in most African countries with an unmet need for contraception resulting in unwanted pregnancies associated with poor maternal and child health outcomes. Although Rwanda has made significant progress in improving maternal and child health, including increasing the availability and coverage of family planning, more can be achieved [1–3]. Currently 48% of married women and 35% of unmarried sexually active women in Rwanda are using a modern contraceptive method [4]. Contraceptive use prevalence is similar across the regions, and in the urban and rural female populations, with an overall national unmet need of 19% [4]. Expansion of the contraceptive options or method mix might reduce this gap.

In recent years, contraceptive vaginal rings (CVRs) have become popular in the countries where they are available. Two CVRs have been marketed in select countries to date: the etonogestrel ethinyl estradiol Nuvaring and the progesterone only Progering® for breastfeeding women [5]. A one-year norethisterone ethinyl estradiol ring is currently in the final stages of registration [6]. Numerous studies have documented the safety, tolerability and efficacy of CVRs, as well as several benefits including menstrual cycle control, ease of use, and being user-controlled [7–13]. Nuvaring clinical trials in Europe and North America have shown good acceptability [14–19], but data from low and middle income countries are limited [20]. Some CVR acceptability studies were conducted in Latin America in the early eighties and showed good acceptability [21–22]. Recent studies in women of reproductive age in India, and in breastfeeding women in Kenya, Nigeria, and Senegal, have also shown good acceptability [23–26].

Research on vaginal rings regained momentum with the development of vaginal microbicides for HIV prevention and multipurpose prevention tools (for prevention of pregnancy, HIV, and other sexually transmitted infections (STIs)) [27–29]. In contrast to CVR research, most studies on HIV preventive or multipurpose vaginal rings acceptability and adherence to date have been conducted in Africa [30–33]. This research highlighted the importance of assessing health and sexual behaviors in depth in order to improve our understanding of vaginal ring acceptability and adherence, especially since vaginal rings might interfere with sexual relationships [34]. The objective of our study is to explore acceptability of CVR (NuvaRing) use in Rwanda using both quantitative and qualitative methods.

Methods

Study design and setting

This acceptability study was a component of a clinical trial we conducted from June 2013 to March 2014 at the Rinda Ubuzima research site located in Kigali, the urban capital city of Rwanda (NCT01796613). This open label single-centre randomized controlled trial of intermittent versus continuous use of a contraceptive vaginal ring aimed to evaluate NuvaRing safety on the vaginal environment but also included an extensive social science component using a mixed methods approach (quantitative and qualitative data collection) to assess NuvaRing feasibility, acceptability, and adherence [35].

The Rwandan National Ethics Committee (approval number 481/RNEC/2013) and the ethics committees of the Institute of Tropical Medicine (ITM) in Antwerp, Belgium (approval number 864/13), the University Teaching Hospital in Antwerp, Belgium (approval number 13/7/85) and the University of Liverpool in Liverpool, UK (approval number RETG000639IREC) approved the study.
Study population

Study participants included women between 18 and 35 years old, willing to provide informed consent, HIV negative, sexually active, and in good physical and mental health. They were not currently using a modern contraceptive method but were interested in and eligible for Nuvaring® use [35].

Study recruitment and procedures

Community mobilizers recruited potential participants at established recruitment sites from previous HIV prevention trials and were, as a result, at above-average risk for HIV/STIs and unplanned pregnancies. The study team screened the women in the study clinic and assessed their eligibility based on the criteria indicated above. Before enrolment, we asked all women whether they would be willing to participate in in depth interviews (IDIs) and/or focus group discussions (FGDs) prior, during and/or after the clinical trial [Fig 1]. At all ring removal follow-up visits, a clinician conducted a physical and pelvic exam, completed the clinic case report forms (CRF), and an interviewer-administered questionnaire (IAQ).

Data collection

We collected quantitative ring use acceptability data as part of the CRFs and IAQs at screening, at enrolment after the first ring insertion, and at every subsequent ring removal follow-up visit [Fig 2]. In addition, at enrolment and each follow-up visit participants completed a self-rating adherence scale and received a diary card to document ring removals and expulsions as well as sexual and vaginal practices that occurred in between study visits within their home. We compared the different data sources for each participant at each data collection time point using

Fig 1. Flow chart of the study process detailing screen failure rates. The study screen flow is presented detailing screen failure rates.

https://doi.org/10.1371/journal.pone.0199096.g001
comparison sheets to identify discrepancies between the data sources. At the last study visit, the study nurses asked participants about any discrepancies identified over the course of the study using open-ended questions that were individually tailored. Finally, we collected anonymous ballot box questionnaires, including a few questions on acceptability, for all participants at the last study visit.

We collected qualitative data at several time points before, during and after the study using IDIs and FGDs [Fig 2]. At the pre-screening visit, 13 IDIs were conducted to adapt and refine the correct meaning and understanding of the structured IAQs prior to enrolment [36–37]. Midway through the study, five mid-trial FGDs with eight to 12 women from both the intermittent and continuous groups (total of 51 women) were conducted to explore CVR acceptability in depth, and to elaborate on contextual issues such as vaginal practices and family planning. We purposively selected women based on previous family planning use (or lack thereof) as well as documented problems using the ring such as deliberate removals and/or spontaneous expulsions. Once the study was completed, we conducted five end-trial FGDs with a total of 49 women who had not previously participated in a FGD and were purposively selected based on their responses to IAQs to further explore their perceptions about the ring and their experiences with deliberate removals and/or spontaneous expulsions. In addition we conducted IDIs with 10 study participants and 10 male partners (not necessarily linked to each other). We purposively selected those 20 interviewees based on specific study related data pertaining to ring acceptability. All IDIs and FGDs were based on structured list of questions and conducted by the same (female) moderator. A male moderator conducted the male partner IDIs. We trained the moderators and allowed them to probe if deemed necessary.
Data analysis

We analyzed the quantitative data using STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.) and reported the results in contingency tables (frequency for categorical data; median and interquartile range (IQR) for continuous data). The authors combined the acceptability data of the two clinical trial groups in this paper because we did not find any statistically significant differences between both groups in those areas.

The study team audio-recorded, transcribed verbatim, and translated all IDIs and FGDs into English. The English transcripts were uploaded into Nvivo 10. We analyzed this data using a deductive, content-analytical approach to assess if the components of the holistic theoretical framework developed by van der Straten (2012) for assessing acceptability of vaginal rings for microbicide delivery were valid in our setting with CVR use [38–39]. The framework includes baseline attributes (socio-demographic attributes), followed by product attributes, relationship attributes, sexual encounter attributes, and the contextual environment. Components from Merkatz’s model on CVR acceptability (2014), such as side effects and satisfaction, were integrated into van der Straten’s framework as well as new elements that emerged from the data [Fig 3] [40]. Two qualitative researchers performed all coding and analysis to compare their coding and reach consensus on divergent issues.

Results

We collected quantitative data for the 120 women enrolled in the trial. One participant withdrew consent after enrolment and did not complete any of the scheduled study visit CRFs or IAQs but she did complete an end of study visit. In total, 104 of the 120 enrolled women participated in at least one IDI and/or FGD and 8 participants had both an IDI and a FGD. The remaining 16 were either not available to attend or not selected. Results are presented based on the components of the van der Straten framework [38–39].

![Fig 3. Theoretical framework used for data collection and analysis as adapted from Van der Straten et al [38] and Merkatz et al [40]. The framework proposed by van der Straten et al [35] was used for data collection and analysis; elements of the NES/EE CVR acceptability model by Merkatz et al [37] such as side effect and bodily changes were added.](https://doi.org/10.1371/journal.pone.0199096.g003)
Baseline characteristics of the study population

Overall, the socio-demographic characteristics between the two clinical trial groups (intermit-
tent and continuous users) were very similar [Table 1]. The median age of the enrolled women
was 28 (IQR: 26–31.9) and the median age of first intercourse was 18 (IQR: 16.5–18.5). The
majority of the women had primary school level of education and were married (60.8%).
Regarding contraception, 65.8% of the women had ever used a contraceptive method (besides
condoms) and most felt that the best family planning method was either injectables (30%) or
condoms (30.8%). Most participants (48.3%) reported using condoms sometimes but not
always in the past three weeks.

Product attributes

General worries and concerns. We asked women at the enrollment visit, prior to initia-
tion of ring use, what worries they had, if any, about using a CVR. Overall, 31.7% of the
women had at least one worry, with the top four worries noted as the ring might come out
(10.8%), be uncomfortable during sex (9.2%), cause infection (7.5%), or not adequately protect
against pregnancy (7.5%). The worries about ring expulsions were echoed during IDIs and
FGDs conducted after the first ring insertion:

“When I inserted the ring for the first time, I was worried, every time I had to go to the toilet, I
would feel like it [the ring] would come out, I had to protect it using my hands...so that if the
ring came out, it would fall into my hands. But this never happened.” (27, unmarried, 1 child)

During the IAQs at ring removal visits, 16% of the women reported at least one worry
about ring use at least one time during the study. However, at the last ring removal visit, only
four women still reported worries with two women reporting that they were worried about
their partner not liking the ring and two women reporting to still be worried about ring
expulsions.

Appearance, odor, and volume. According to the IDI and FGD data, the majority of the
women had no issues with the appearance, odor, and volume of the ring. A few women noted
that they were concerned with the size before they had ever inserted a ring, while others argued
that if it were any smaller, it might not fit all vaginas. When asked to describe the ring, women
described it as soft and cold with either no smell, smelling like chewing gum, or a pleasant
smell. They also noted that the ring was white or beige when inserted but came out yellow after
use. The women were, however, not concerned about this because they had been informed
about potential discoloration during the study visits.

Male partners of study participants voiced several concerns about the ring during IDIs
(n = 10) at the end of the study. Most of the concerns were related to potential side effects of
ring use (e.g. illness, infertility) and about ring appearance. Male partners did not have an
opportunity to see the ring prior to insertion, and they associated the word ‘ring’ (in Kinyar-
wanda impeta) with a metal ring. They were reassured when they eventually saw a ring.

“I wanted to see what it looked like, when I saw it, I found out that it is flexible, it would not
cause cancer, nothing on it that would harm people, so I told her, you insert it, I am not wor-
ried about it and I did not experience any problem.” (30, married, 2 children)

Ease of use. The quantitative and qualitative data revealed that, overall, women found the
ring easy to insert and remove. At the enrolment visit, immediately after inserting the ring for
Table 1. Socio-demographic characteristics of enrolled participants.

| Baseline characteristics, N (%) | Intermittent use (N = 60) | Continuous use (N = 60) | All participants (N = 120) |
|---------------------------------|---------------------------|-------------------------|---------------------------|
| **Age in years (median; IQR)**  |                           |                         |                           |
|                                 | 28 (25.5; 31)             | 28.5 (26; 32)           | 28 (26; 31.9)             |
| **Highest Level of Education**  |                           |                         |                           |
| No schooling                    | 9 (15.0)                  | 6 (10.0)                | 15 (12.5)                 |
| Primary school not completed    | 15 (25.0)                 | 21 (35.0)               | 36 (30.0)                 |
| Primary school completed        | 24 (40.0)                 | 20 (33.3)               | 44 (36.7)                 |
| Secondary school not completed  | 8 (13.3)                  | 9 (15.0)                | 17 (14.2)                 |
| Secondary school completed      | 2 (3.3)                   | 2 (3.3)                 | 4 (3.3)                   |
| More than secondary school      | 2 (3.3)                   | 2 (3.3)                 | 4 (3.3)                   |
| **Marital Status/Home Situation** |                         |                         |                           |
| Married                         | 37 (61.7)                 | 36 (60.0)               | 73 (60.8)                 |
| Not married, regular sex partner, living together | 16 (26.7) | 16 (26.7) | 32 (26.7) |
| Not married, regular sex partner but not living together | 7 (11.7) | 8 (13.3) | 15 (12.5) |
| **Income, Rwandese Franc (RwF)** |                         |                         |                           |
| Own Income                      | 37 (30.8)                 | 34 (28.3)               | 71 (59.2)                 |
| Average weekly Income           | 16.828 RwF                | 24.413 RwF              | 20.685 RwF                |
| **Age of first intercourse, in years (median, IQR)** | 18 (16–18) | 18.5 (16.5–20) | 18 (16.5–18.5) |
| **Lifetime male sexual partners:** |                           |                         |                           |
| 1–3                             | 51 (85.0)                 | 53 (88.3)               | 104 (86.7)                |
| 4 or more (range 4–300)         | 9 (15.0)                  | 7 (11.7)                | 16 (13.3)                 |
| **Other sexual partners in past 3 months** | 2 (3.3) | 2 (3.3) | 4 (3.3) |
| **Pregnancies**                 |                           |                         |                           |
| 0                               | 2 (3.3)                   | 3 (5.0)                 | 5 (4.2)                   |
| 1                               | 12 (20.0)                 | 10 (16.7)               | 22 (18.3)                 |
| 2                               | 22 (36.7)                 | 17 (28.3)               | 39 (32.5)                 |
| 3 or more                       | 24 (40.0)                 | 30 (50.0)               | 54 (45.0)                 |
| **Contraception history**       |                           |                         |                           |
| None                            | 19 (31.6)                 | 22 (36.6)               | 41 (34.2)                 |
| Contraceptive                   | 41 (68.3)                 | 38 (63.3)               | 79 (65.8)                 |
| Injectables       | 32 (53.3)                 | 27 (45.0)               | 59 (49.2)                 |
| Pills                          | 11 (18.3)                 | 18 (30.0)               | 29 (24.2)                 |
| Implant                        | 2 (3.3)                   | 3 (5.0)                 | 5 (4.2)                   |
| IUD (Copper)                   | 1 (1.7)                   | 0 (0)                   | 1 (0.8)                   |
| Beads or counting              | 2 (3.3)                   | 0 (0)                   | 2 (1.7)                   |
| **Best FP in your opinion**    |                           |                         |                           |
| Condoms                        | 15 (25.0)                 | 22 (36.7)               | 37 (30.8)                 |
| Injections                      | 19 (31.7)                 | 17 (28.3)               | 36 (30.0)                 |
| Oral contraception             | 11 (18.3)                 | 7 (11.7)                | 18 (15.0)                 |
| Implant                        | 6 (10.0)                  | 4 (6.7)                 | 10 (8.3)                  |
| IUD (Copper)                   | 4 (6.7)                   | 4 (6.7)                 | 8 (6.7)                   |
| Beads and Counting             | 2 (3.3)                   | 2 (3.3)                 | 4 (3.4)                   |
| **Condom use**                 |                           |                         |                           |
| Always                         | 12 (20.0)                 | 9 (15.0)                | 21 (17.5)                 |
| Sometimes but not always       | 24 (40.0)                 | 35 (58.3)               | 59 (49.2)                 |
| Never                          | 23 (38.3)                 | 16 (26.7)               | 39 (32.5)                 |

† More than one answer possible
* Question asked as ‘What is the best method for family planning, in your opinion?’
** Defined as condom use during vaginal sex in the past three weeks.
*** This was the only characteristic that was significantly different between the two arms (p = 0.045).

https://doi.org/10.1371/journal.pone.0199096.t001
the first time, only five participants said that they did not find the ring easy to insert and two participants said that insertion was painful. Almost all women (96.7%) thought that reinsertion would be easy. By the end of the study, all but one participant stated that ring insertion was easy.

**Duration of use.** During FGDs and IDIs most participants thought that the duration of use of each individual ring should be increased (i.e. longer than the current 3 weeks) with suggested preferred use durations ranging from 2 months to 10 years. Women compared these durations to other methods "like 3 months injection, like 3 years implant, like 10 years IUD". Reasons cited for preferring increased use duration were potential lower costs, having to remove and insert the ring less often, and maintaining increased vaginal lubrication as women reported that the ring increased vaginal lubrication but that “the lubrication went down when the medicine [in the ring] finishes”. Most male partners tended to have questions about the duration of ring use (e.g. “how long should it be used?”) and one partner said the duration was too short.

**Feel.** Most women liked that they did not feel the ring during daily activities (reported by IAQ by 95.4% of the women at ring removal visits during ring use and by 95.8% of the women at the last ring removal visit) but a few women said that not feeling the ring made them worry that it had fallen out. During interviews only very few participants reported that the ring caused some discomfort during use, and one of those women reported that the initial discomfort was caused by improper insertion.

**Bodily changes.** Women reported an overall increase in vaginal wetness or lubrication in the IAQs (52.9% of the women at least once during ring use and 74.8% at the last ring removal visit). This was generally perceived as a positive attribute, which was corroborated by the qualitative data. Only two women reported that they did mind the increased lubrication but in their opinion, their partners did not mind it. At the last ring removal visit, one of those women still reported the increased lubrication was a problem for her but not for her partner.

At the last ring removal visit, 8.3% of the intermittent users and 57.6% of the continuous users reported to no longer have menstrual periods. This was not perceived as a problem except for one continuous user:

“I feared that I got a tumor in my uterus because my menses stayed inside my body I am wondering where the menses goes if they are not coming out?” (32, unmarried, 1 child)

**Side effects.** Women appreciated the lack of negative side effects such as headache and back pain, which they perceived as common side effects of other hormonal contraceptive methods.

“I stopped using the other methods because of those side effects that used to happen to me. I even had Norplant, but stopped it because of dizziness, headache, bleeding, all those were going to kill me. But since I have started using this ring, nothing happened to me”. (35, married, 6 children)

**Relationship attributes**

In the IAQs, we asked women how they felt about their relationships in general. At the last ring removal visit, 60.8% of the women reported to be very satisfied, and 37.5% moderately satisfied, in their relationships. Only one woman reported to be very dissatisfied in her relationship. 60% of participants described the most important factors for a happy and satisfactory
relationship as having a partner who helped, cared for and/or provided (financially) for the family. Women also found sharing responsibilities and discussing or planning together important (25.8%) for a satisfactory relationship whereas alcohol abuse (11.7%) and having other partners (6.7%) were the main causes of dissatisfaction. Two women reported cases of physical abuse (including one rape).

**Couple communication.** At enrolment 93.3% of the women had told their main partner that they would be wearing the ring and the eight women who had not yet told their partners but intended to do so later on. At the last ring removal visit, all but one woman had told their partners that they were participating in a vaginal ring study. These attitudes about contraceptive use and communication within the couple were echoed in interviews as well:

“If the man does not want you to use contraceptives, then you have to accept what he asks you to do, he is the head of the house”. (25, not married, 1 child)

**Decision making about sex.** Based on the qualitative data collected, it was clear that women in our study felt that if they are not satisfied during sex, they cannot tell their partners. They thought that if a woman does not want sex, the man would force himself onto her. However, they also reported that women had ways to get around this, for example, by pretending to have menses.

An interesting finding was that most women reported that ring use stimulated conversations with their partners about increased lubrication and sexual desire, but also about family planning and more general relationship topics. Mutual sexual gratification is seen as an important element in the relationship and women felt that if sex is mutually satisfying, overall couple communication is better.

**Sexual encounter attributes**

**Sexual comfort.** At the beginning of the study, before ring use, 58.3% of the women thought it important that their main partner would not feel the ring during sex. At the last ring removal visit, 82.5% of the women reported to never have felt the ring during vaginal sex. However, 52.5% of the women reported that their partner had told them that he had felt the ring during vaginal sex at least once during ring use. Before first ring use, women thought that whether or not their partner actually felt the ring would not affect acceptability but if the ring caused either of them discomfort during sex, acceptability would be negatively affected. Once women had experienced using the ring, only 3.3% reported at least once during ring use that their partner disliked the way it felt during sex. At the last ring removal visit, no woman reported that her partner disliked the way it felt during sex. This was corroborated by the IDIs with male partners: six of the 10 interviewees reported having felt the ring during sex but said that this was not a problem.

**Sexual pleasure.** Most women (80.6%) reported at least once during ring use that the ring made sex feel better and at the last ring removal visit, this increased to 87.5%. The FGDs and the IDIs confirmed this finding [Fig 3].

“Really I would not feel any desire of men. It is true, when I was using contraceptive injections I was like a man. I was very dry. But today, I am the one who calls him and tells him that I am feeling well and actually tells him that I am ready for sexual intercourse.” (31, married, 5 children)

The increased vaginal lubrication as well as increased sexual desire led one participant’s partner to state, “This ring should be promoted as a sex enhancer”.
Overall satisfaction
Overall satisfaction has been shown to be a good indicator of future use and adherence to a product. In our study we found that women were very satisfied with only one woman at enrollment stating that she thought that the CVR was the best method for family planning compared to 98.3% of the women stating this at the last ring removal visit. These same women also said that they would recommend a CVR to others. This is in the context of only two women ever having used a vaginal ring prior to study participation.

Willingness to pay
The cost of a family planning method needs to be taken into consideration when evaluating overall acceptability. We asked how much women would be willing to pay for a CVR like the one they wore in the study. Only 0.3% women stated that they would not be willing to pay for the ring but that they would prefer it to be available free of charge at family planning centers. Not a single woman reported that she was willing to pay more than 17,000 Rwandan francs (Rwf) per ring (equivalent to about 20 USD at the time of writing), and most women (95.8%) reported to be willing to pay between 1–8,500 Rwf (up to 10 USD) per ring.

Contextual environment
The contextual environment defined here as the overall beliefs and attitudes about family planning and sexuality in Rwanda, the community perceptions of research, and the experiences of participation in this trial, plays a large role in the overall acceptability and uptake of any new product. Many participants and their partners were aware of the fact that the Rwandan government recommends three children per family and child spacing. This was apparent in the FGDs, in which women mentioned that a typical family has two to four children, and cited the benefits of spacing children.

Community perceptions about research relayed by enrolled and excluded women and their partners seemed polarized. Screened participants mentioned rumors in all end trial FGDs and several IDIs. When probed about these rumors, women elaborated about their own communities and experiences mentioning as the main rumor that at the study site (Rinda Ubuzima), the uterus and ovaries were removed and sold or thrown out. Community members were also worried about sterilization due to organ removal, to ring use, or to both. Enrolled participants reported that other women often did not join the study because they feared the pelvic exam and the ring itself could cause health problems, such as bleeding or cancer of the area where it was placed, and even death. Despite these negative rumors, community members actively tried to be recruited into the study for a variety of reasons: access to the ring, monetary reimbursement for travel and time spent at the clinic, and testing and treatment for curable STIs free of charge.

Discussion
Like any new product, initial worries were recorded (by 31% of the women), but reduced over time with usage; in the beginning worries were focused on spontaneous expulsions but this changed during the course of the study with worries becoming more focused on male partner perceptions and concerns. Once the participants had ring use experience, the method of contraception perceived as being the best, changed from condoms (reported by 30.8% of the women at enrollment) to NuvaRing® (reported by 98.3% of the women at the last ring removal visit). A high level of acceptability following actual use has been documented in other studies of new contraceptive or HIV prevention methods, and suggests that self-reported
acceptability based on hypothetical use might not be valid [18]. Appropriate counseling regarding correct use and side-effects can reduce anxiety associated with first time use and as a result enhance initial uptake and acceptability [18, 24, 40–41].

Self-reported comfort with one’s genitals as well as experience using other vaginal products such as tampons were significantly associated with willingness to try the vaginal ring in a number of studies, but not in others [14, 42–44]. None of our participants reported to ever have used tampons, but vaginal sexual and hygiene practices are common in Rwandan culture. As a result, most women are comfortable with their genitalia [41,45–46]. Previous research has shown the important role of sexual gratification in sexual encounters for both women and men [41]. These cultural norms around sexuality, including vaginal practices such as labial elongation as well as ‘wet’ sex, positively influenced the acceptance of NuvaRing [45–46].

The participants in our study engaged in several traditional vaginal practices and found the ring easy to use. In terms of acceptability, the ring’s appearance did not seem to be an important issue, in line with findings from a progesterone-only CVR study in three African countries [20], but in contrast to findings from a progesterone-only CVR study in Brazil [22]. The latter showed that 32% of the participants did not like the discoloration of the ring, referring to it as dirty [22].

The lack of side effects was seen as a major advantage over other family planning methods as was the increased lubrication. This is in line with Rwandan cultural sexual norms where both men and women see ‘wet’ sexual intercourse as desirable. These results highlight the importance of the contextual elements. Further research is needed in other countries that have different cultural norms around sexuality such as settings where dry sex is a common preference. Most participants would have preferred to leave each individual ring in place for longer than the currently licensed three weeks, as has been shown in other studies [26–27]. As stated above, the fact of no longer having of menstrual periods was not perceived as a problem in our study.

Overall, no women reported that using the ring had negative effects on their sexual relationships and feeling the ring during intercourse was not an important issue. Prior to using the ring, women felt that discomfort for their male partner during sex related to the ring would impact acceptability but after using the ring, the majority of women did not report that the ring caused their partner discomfort. These findings regarding sexual comfort are in line with other studies [18–19]. Disturbances of sexual intercourse for a variety of reasons are crucial determinants of acceptability and adherence as well as good indicators of method continuation as noted by Sabatini [47]. However, the literature is not consistent regarding the effect of ring use on sex frequency and pleasure. Some studies have shown no effect on sex frequency and only a slight effect on pleasure but other studies, like our study, have shown a significant improvement in pleasure accompanied by increases in sex frequency [24, 48].

The CVR is a female initiated product but women felt that their partners needed to know that they were using the ring (even if they did not feel it during sex) since the man, as head of the household is seen as the decision maker regarding family planning. This is in line with previous studies highlighting that relationship attributes play a significant role in assessing overall acceptability (Woodsong et al 2008) [39]. Being part of the study and using the ring led to more communication within the couple about their sexual relationships and about family planning. This in turn led to more discussions surrounding decision-making about sex. Most women felt that this increased communication improved their overall relationship. This interesting finding has been noted in other studies and could be a potential avenue for increased family planning counseling/couple counseling during and after clinical trial implementation [48].
Limitations

Our study included a relatively small number (N = 120) of women willing to participate in a clinical trial, at high risk of HIV and other urogenital infections and from an urban population in Kigali. Such attitudes and beliefs towards CVRs might be different in rural areas of Rwanda and are not generalizable to the whole country. In addition we did not have a control group of women who used other modern family planning methods or used none at all. A substantial proportion of the study participants had, however, used other modern family planning methods prior to joining our study. They could therefore compare their experiences with CVR use to other methods.

It is well documented that data on acceptability and acceptability within a clinical trial setting do not necessarily reflect the real-life situation due to higher participant and study staff motivation, higher levels of support provided by study staff, and pro-active follow-up [49, 50]. When rolling out a new product to a larger population, product packaging, labeling, storage requirements, and service delivery should also be assessed. We did not do so but note that NuvaRing can be stored at room temperature [39, 51]. Should NuvaRing be seriously considered for roll out in Rwanda, it would also be important to assess the views of policy makers and advocacy groups [51].

Conclusions

Acceptability of the Nuvaring was high in Kigali, Rwanda. Rolling out this method would increase the contraceptive method mix and lower unmet family planning need. The CVR is a female initiated method but, through the analysis of both quantitative and qualitative data, couple communication and involvement of the male partners in contraception/family planning decision-making appeared crucial in acceptance of the method. Although we did not assign values to the attributes, our data suggest that ring acceptability depended more on the relationship and socio-cultural context than on product attributes. We therefore believe that it is important that acceptability studies take a holistic approach by taking not only contraceptive efficacy and side effects into account but also the broader potential benefits including effects on sexuality.

Acknowledgments

We would like to thank EDCTP, the Ring Plus study group and study participants for making this study possible. In addition to the authors, the members of the Ring Plus Study Group are (in alphabetical order):

Irith De Baetselier MSc, Jozefien Buyze PhD, Vicky Cuylaerts, Gloria Gahindu, Liselotte Hardy, Vicky Jespers PhD, Joris Menten, Viateur Musengamana, Jean Claude Ndagijimana MD, Raffaella Ravinetto, Céline Schurmans, and Harry Van Loen.

The lead author for this group is Irith De Baetselier (idebaetselier@itg.be).

Author Contributions

Conceptualization: Evelyne Kestelyn, Jennifer Ilo Van Nuil, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

Formal analysis: Evelyne Kestelyn, Jennifer Ilo Van Nuil, Marie Michelle Umulisa, Grace Umutoni, Alice Uwingabire, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

Funding acquisition: Tania Crucitti, Janneke van de Wijgert.
**Investigation:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Marie Michelle Umulisa, Alice Uwingabire, Lambert Mwambarangwe, Mireille Uwineza, Stephen Agaba.

**Methodology:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

**Project administration:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

**Software:** Grace Umutoni.

**Supervision:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Marie Michelle Umulisa, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

**Validation:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Grace Umutoni.

**Writing – original draft:** Evelyne Kestelyn, Jennifer Ilo Van Nuil.

**Writing – review & editing:** Evelyne Kestelyn, Jennifer Ilo Van Nuil, Marie Michelle Umulisa, Grace Umutoni, Alice Uwingabire, Lambert Mwambarangwe, Mireille Uwineza, Stephen Agaba, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux.

**References**

1. Dhont N, Ndayisaba GF, Pettier CA, Nzabonimpa A, Temmerman M, van de Wijgert J. Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care. 2009 Dec; 14(6): 420–425. https://doi.org/10.3109/13625189093340584 PMID: 19929645

2. Elul B, Delvaux T, Munyana E, Lahuerta M, Horowitz D, Ndagije F, et al. Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda. AIDS. 2009 Nov; 23 Suppl 1: S19–S26. https://doi.org/10.1097/01.aids.0000363774.91376.dc PMID: 20081385

3. Leslie JA, Munyambanza E, Adamchak SE, Janowitz B, Grey TW, Kirota K. Without strong integration of family planning into PMTCT services in Rwanda, clients remain with a high unmet need for effective family planning. Afr J Reprod Health. 2010 Dec; 14(4 Spec no.): 144–146.

4. Rwanda Demographic and Health Survey 2014–2015 Key indicators. National Institute of Statistics of Rwanda, Ministry of Finance and Economic Planning, Ministry of Health, Kigali, Rwanda, The DHS Program, ICF International, Rockville, Maryland, USA. July 2015.

5. Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception. 2010 Nov; 82(5): 428–434. https://doi.org/10.1016/j.contraception.2010.05.016 PMID: 20933116

6. Brache V, Payan LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception. 2013 Mar; 87(3): 264–270. https://doi.org/10.1016/j.contraception.2012.08.037 PMID: 23040125

7. Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010; 82(5):418–427. https://doi.org/10.1016/j.contraception.2010.04.012 PMID: 20933115

8. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®). International Journal of Women’s Health. 2010 Nov; 2: 401–409. https://doi.org/10.2147/IJWH.S162 PMID: 21151688

9. Bitzer J. The vaginal ring (NuvaRing®) for contraception in adolescent women. Gynecol Endocrinol. 2012 Feb; 28(2): 125–9. https://doi.org/10.3109/09513590.2011.579665 PMID: 21615237

10. Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing®. Ther Clin Risk Manag. 2008 Apr; 4(2): 441–451. PMID: 18728640

11. Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, Nuvaring®, a decade after its introduction. Eur J Contracept Reprod Health Care. 2012 Dec; 17(6): 415–427. https://doi.org/10.3109/13625187.2012.713535 PMID: 23113628

12. Lopez LM, Grimes DA, Gallo MF, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2010 Mar;(3): CD003552. https://doi.org/10.1002/14651858.CD003552.pub3 PMID: 20238323

13. Carr SL, Gaffield ME, Dragoman MV, Phillips S. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: a systematic review. Contraception. 2016 Sep; 94(3): 253–261. https://doi.org/10.1016/j.contraception.2015.04.001 PMID: 25869631
14. Terrell LR, Tanner AE, Hensel DJ, Blythe MJ, Forutenberg JD. Acceptability of the vaginal contraceptive ring among adolescent women. J Pediatr Adolesc Gynecol. 2011 Aug;(24): 204–210. https://doi.org/10.1016/j.jpag.2011.02.003 PMID: 21454109

15. Gilliam ML, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol. 2010 Mar; 115(3): 503–510. https://doi.org/10.1097/AOG.0b013e3181cf45dc PMID: 20177280

16. Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception. 2006 May; 73(5): 488–492. https://doi.org/10.1016/j.contraception.2005.11.003 PMID: 16627032

17. Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contracept Reprod Health Care. 2002 Dec; 7(sup 2): 31–36. https://doi.org/10.1080/13625182.2002.11949333 PMID: 29243955

18. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, Nuvaring: an international study of user acceptability. Contraception. 2003 Mar; 67(3): 187–194. PMID: 12618252

19. Sarkar NN. The combined contraceptive vaginal device (NuvaRing): a comprehensive review. Eur J Contracept Reprod Health Care. 2005 Jun; 10(2): 73–8. https://doi.org/10.1080/13625180500131683 PMID: 16147810

20. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GI, Wyss R, et al. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Contraception. 1990 Feb; 41(2): 151–167. PMID: 2107057

21. Faundes A, Hardy E, Reyes C, Pastene L, Portes-Carrasco R. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries. Contraception. 1981 Oct; 24(4): 393–414. PMID: 7318435

22. Hardy EE, Reyes Q, Gomez F, Portes-Carrasco R, Faundes A. User’s perception of the contraceptive vaginal ring: a field study in Brazil and the Dominican Republic. Stud Fam Plann. 1983 Nov; 14(11): 284–290. PMID: 6417842

23. Soni A, Garg S, Bangar R. Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspective. J Obstet Gynaecol India. 2013 Oct; 63(5): 337–341. https://doi.org/10.1007/s13224-013-0391-5 PMID: 24431671

24. Saumya R, Clark H, Rajamani D, Ishaku S, Mané B, Obare F, et al. 2015 Dec. “Progestosterone vaginal ring: results of a three-country acceptability study.” New York: Population Council.

25. RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progestosterone vaginal ring: introducing a contraceptive to meet the need of breastfeeding women. Contraception. 2013 Nov; 88(5): 591–598. https://doi.org/10.1016/j.contraception.2013.05.004 PMID: 23769015

26. Pandit SN, Chauhan AR, Anagani M, Reddy S, Birla A, Ray SK. Multicenter study of contraceptive vaginal ring (NuvaRing®) in normal daily practice in Indian women. J Obstet Gynaecol India. 2014 Dec; 64(6): 409–416. https://doi.org/10.1007/s13224-014-0559-7 PMID: 25489144

27. Thurman AR, Clark MR, Hurlbut JA, Doncel GF. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health. 2013 Oct; 5: 695–708. https://doi.org/10.2147/IJWH.S34030 PMID: 24174884

28. van der Straten A, Montgomery ET, Nel A, Cheng H, Wenger L, Young K, et al. High acceptability of a vaginal ring as a microbicide delivery method for HIV prevention in African women. Proceedings of the International AIDS Conference; 2011 July 17–20; Rome, Italy.

29. van der Straten A, Panther L, Laborde N, Hoesley CJ, Cheng H, Husnik MJ, et al. Adherence and acceptability of a multirug vaginal ring for HIV prevention in a phase I study in the United States. AIDS Behav. 2016 Nov; 20(11): 2664–2663. https://doi.org/10.1007/s10461-016-1299-8 PMID: 26837628

30. Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a Dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec; 375(22): 2133–2143. https://doi.org/10.1056/NEJMoa1602046 PMID: 27959766

31. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing Dapivirine for HIV-1 prevention in women. N Engl J Med. 2016 Dec; 375(22): 2121–2132. https://doi.org/10.1056/NEJMoa1506110 PMID: 26909002

32. Nel A, Bekker LG, Bukusi E, Hellström E, Kotze P, Louw C, et al. Safety, acceptability and adherence of Dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS One. 2016 Mar; 11(3): e0147743. https://doi.org/10.1371/journal.pone.0147743 PMID: 26963505

33. Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeter K, Atujuma M, et al. Acceptability and use of a Dapivirine vaginal ring in a phase III trial. AIDS. 2017 May; 31(8): 1159–1167. https://doi.org/10.1097/QAD.0000000000001452 PMID: 28441175

34. Dapivirine vaginal ring in a microbicid e clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS One. 2016 Mar; 11(3): e0147743. https://doi.org/10.1371/journal.pone.0147743 PMID: 26963505
34. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One. 2010 Jul; 5(7): e11600. https://doi.org/10.1371/journal.pone.0011600 PMID: 20657778

35. Schumans C, De Baetselier I, Kestelyn E, Jespers V, Delvaux T, Agaba SK, et al. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy. BMC Public Health. 2015 Apr; 15: 348. https://doi.org/10.1186/s12889-015-1680-y PMID: 25880636

36. Novak A, de la Loge C, Abetz L. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing®. Pharmacoeconomics. 2004; 22(4): 245–256. PMID: 14974874

37. Isidori AM, Pozza C, Esposito K, Giugliano D, Morano S, Vignozzi L, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010 Mar; 7(3): 1139–1146. https://doi.org/10.1111/j.1743-6109.2009.01635.x PMID: 19968774

38. van der Straten A, Montgomery ET, Nel A, Cheng H, Wenger L, Young K, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012; 16: 1775–1786. https://doi.org/10.1007/s10461-012-0215-0 PMID: 22644068

39. Woodsong C, Simons-Rudolph A, Allemann P. A flexible theoretical framework for investigating acceptability in microbicide clinical trials. Proceedings from the Microbicides Conference; 2008 24–27 February, Delhi, India (Abstract #TC-131).

40. Merkatz RB, Plagianos M, Hoskin E, Cooney M, Hewett PC, Mensch BS. Acceptability of the nestor-1®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction. Contraception. 2014 Nov; 90(5): 514–521. https://doi.org/10.1016/j.contraception.2014.05.015 PMID: 24993487

41. Skafte I, Silberschmidt M. Female gratification, sexual power and safe sex: female sexuality as an empowering resource among women in Rwanda. Cult Health Sex. 2014; 16(1): 1–13. https://doi.org/10.1080/13691058.2013.812508 PMID: 23895629

42. Carey AS, Chiappetta L, Tremont K, Murray PJ, Gold MA. The contraceptive vaginal ring: female adolescents’ knowledge, attitudes and plans for use. Contraception 2007 Dec; 76(6): 444–450. https://doi.org/10.1089/cpr.2007.07.03 PMID: 18061702

43. Tepe M, Mestad R, Secura G, Allsworth JE, Madden T, Peipert JF. Association between tampon use and choosing the contraceptive vaginal ring. Obstet Gynecol. 2010 Apr; 115(4): 735–739. https://doi.org/10.1097/AOG.0b013e3181d41c64 PMID: 20308832

44. Shimoni N, Westhoff C. Review of the vaginal contraceptive ring (NuvaRing®). J Fam Plann Reprod Health Care. 2008 Oct; 34(4): 247–250. https://doi.org/10.1783/147116908766000370 PMID: 18854070

45. Lar森 J. The social vagina: labia elongation and social capital among women in Rwanda. Cult Health Sex. 2010 Oct; 12(7): 613–626. https://doi.org/10.1080/13691058.2010.498057 PMID: 23685297

46. Koster M, Price LL. Rwandan female genital modification: elongation of the Labia minora and the use of local botanical species. Cult Health Sex. 2008 Feb; 10(2): 191–204. https://doi.org/10.1080/13691050701775076 PMID: 18247211

47. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006 Sep; 74(3): 220–223. https://doi.org/10.1016/j.contraception.2006.03.022 PMID: 16904415

48. Marlow HM, Tolley EE, Kohlric R, Mehendalec S. Sexual communication among married couples in the context of a microbicide clinical trial and acceptability study in Pune, India. Cult Health Sex. 2010 Nov; 12(8): 899–912. https://doi.org/10.1080/13691058.2010.508844 PMID: 20721768

49. Tolley EE, Morrow KM, Owen DH. Designing a multipurpose technology for acceptability and adherence. Antiviral Res. 2013 Dec; 100 Suppl: S54–S59. https://doi.org/10.1016/j.antiviral.2013.09.029 PMID: 24188706

50. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect. 2005 Jun; 81(3): 193–200. https://doi.org/10.1136/sti.2003.007153 PMID: 15923284

51. Severy L, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005 Mar; 9(1): 121–131. https://doi.org/10.1007/s10461-003-1687-y PMID: 15812619